Adaptimmune Therapeutics (ADAP) Short Interest Ratio & Short Volume $0.59 -0.02 (-3.12%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$0.59 0.00 (0.00%) As of 01/31/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Adaptimmune Therapeutics Short Interest DataAdaptimmune Therapeutics (ADAP) has a short interest of 5.76 million shares. This marks a 4.73% increase in short interest from the previous month. The short interest ratio (days to cover) is 2.7, indicating that it would take 2.7 days of the average trading volume of 1.14 million shares to cover all short positions.Current Short Interest5,760,000 sharesPrevious Short Interest5,500,000 sharesChange Vs. Previous Month+4.73%Dollar Volume Sold Short$3.50 millionShort Interest Ratio2.7 Days to CoverLast Record DateJanuary 15, 2025Outstanding Shares255,880,000 sharesPercentage of Shares Shorted2.25%Today's Trading Volume620,928 sharesAverage Trading Volume1,143,532 sharesToday's Volume Vs. Average54% Short Selling Adaptimmune Therapeutics? Sign up to receive the latest short interest report for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartADAP Short Interest Over TimeADAP Days to Cover Over TimeADAP Percentage of Float Shorted Over Time Adaptimmune Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/15/20255,760,000 shares $3.50 million +4.7%N/A2.7 $0.61 12/31/20245,500,000 shares $2.96 million +8.7%N/A2.6 $0.54 12/15/20245,060,000 shares $2.94 million -24.7%N/A2.8 $0.58 11/30/20246,720,000 shares $4.84 million -2.8%N/A4.1 $0.72 11/15/20246,910,000 shares $4.05 million +29.2%N/A4.7 $0.59 10/31/20245,350,000 shares $3.88 million -3.8%N/A4.5 $0.73 10/15/20245,560,000 shares $4.89 million -8.7%N/A3.5 $0.88 9/30/20246,090,000 shares $5.79 million -13.0%N/A3.6 $0.95 9/15/20247,000,000 shares $7.77 million +2.5%N/A3.9 $1.11 8/31/20246,830,000 shares $8.67 million -4.2%N/A3.7 $1.27 Get the Latest News and Ratings for ADAP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/15/20247,130,000 shares $7.77 million No ChangeN/A3.3 $1.09 7/31/20247,130,000 shares $9.48 million +13.2%N/A3.5 $1.33 7/15/20246,300,000 shares $7.84 million +11.7%N/A4 $1.25 6/30/20245,640,000 shares $5.50 million +15.1%N/A3.6 $0.97 6/15/20244,900,000 shares $4.95 million +6.1%N/A3.3 $1.01 5/31/20244,620,000 shares $5.22 million +34.3%N/A2.8 $1.13 5/15/20243,440,000 shares $4.27 million -2.3%N/A2.5 $1.24 4/30/20243,520,000 shares $4.19 million +3.2%N/A2.3 $1.19 4/15/20243,410,000 shares $3.58 million +6.6%N/A1.7 $1.05 3/31/20243,200,000 shares $5.06 million +2.9%N/A1.7 $1.58 3/15/20243,110,000 shares $4.60 million +11.1%N/A1.7 $1.48 2/29/20242,800,000 shares $4.40 million -4.4%N/A1.6 $1.57 2/15/20242,930,000 shares $3.66 million -37.8%N/A2.1 $1.25 1/31/20244,710,000 shares $4.52 million -18.4%N/A3.8 $0.96 1/15/20245,770,000 shares $4.75 million +1.2%N/A9.3 $0.82 12/31/20235,700,000 shares $4.52 million -6.9%N/A9.6 $0.79 12/15/20236,120,000 shares $2.75 million -0.8%N/A12 $0.45 11/30/20236,170,000 shares $3.09 million +3.0%N/A14.4 $0.50 11/15/20235,990,000 shares $3.00 million +2.4%N/A14.3 $0.50 10/31/20235,850,000 shares $3.16 million -12.6%N/A14.2 $0.54 10/15/20236,690,000 shares $4.39 million +12.1%N/A14.7 $0.66 9/30/20235,970,000 shares $4.66 million -1.3%N/A12.2 $0.78 9/15/20236,050,000 shares $4.91 million +3.1%N/A10.3 $0.81 8/31/20235,870,000 shares $4.58 million +1.9%N/A8.3 $0.78 8/15/20235,760,000 shares $4.49 million +0.4%N/A6.5 $0.78 7/31/20235,740,000 shares $5.41 million +1.4%3.9%6.5 $0.94 7/15/20235,660,000 shares $5.10 million -5.5%3.8%6.2 $0.90 6/30/20235,990,000 shares $5.54 million -19.6%4.1%6.3 $0.93 6/15/20237,450,000 shares $7.52 million -25.2%5.1%8.4 $1.01 5/31/20239,960,000 shares $10.16 million +8.7%6.8%11.6 $1.02Is this Elon’s true agenda? (Ad)All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors have all turned to my business partner and I for our thoughts on the market. And with every investor in America wondering what Elon is going to do now that he's in Washington, this is what we tell themClick here for my report 5/15/20239,160,000 shares $12.73 million +2.0%6.2%12.1 $1.39 4/30/20238,980,000 shares $12.75 million +19.9%6.2%12.5 $1.42 4/15/20237,490,000 shares $10.19 million +11.3%5.1%11.6 $1.36 3/31/20236,730,000 shares $7.34 million +28.7%4.6%11.9 $1.09 3/15/20235,230,000 shares $5.91 million +81.0%3.6%9.6 $1.13 2/28/20232,890,000 shares $5.12 million +1.8%2.0%6.5 $1.77 2/15/20232,840,000 shares $4.69 million +1.4%2.0%8.4 $1.65 1/31/20232,800,000 shares $5.24 million +3.3%1.9%6.4 $1.87 1/15/20232,710,000 shares $5.07 million -8.1%1.9%5.1 $1.87 12/30/20222,950,000 shares $4.31 million +7.7%2.0%5.6 $1.46 12/15/20222,740,000 shares $3.73 million -1.4%1.9%5.3 $1.36 11/30/20222,780,000 shares $6.03 million -26.1%1.9%5.3 $2.17 11/15/20223,760,000 shares $8.95 million +12.6%2.6%7.6 $2.38 10/31/20223,340,000 shares $4.74 million -10.0%2.3%7.9 $1.42 10/15/20223,710,000 shares $4.19 million -6.6%2.6%9.3 $1.13 9/30/20223,970,000 shares $4.27 million +7.0%2.8%13.5 $1.08 9/15/20223,710,000 shares $6.01 million +0.3%2.6%12.3 $1.62 8/31/20223,700,000 shares $7.33 million +1.7%2.6%11.6 $1.98 8/15/20223,640,000 shares $8.77 million -2.2%2.5%10.6 $2.41 7/31/20223,720,000 shares $6.88 million -7.9%2.6%9.7 $1.85 7/15/20224,040,000 shares $6.91 million +3.3%2.8%8.4 $1.71 6/30/20223,910,000 shares $6.65 million -4.6%2.7%6.9 $1.70 6/15/20224,100,000 shares $6.60 million -4.7%2.9%7.2 $1.61 5/31/20224,300,000 shares $6.19 million +0.5%3.1%6 $1.44 5/15/20224,280,000 shares $6.03 million -5.5%3.1%4.4 $1.41 4/30/20224,530,000 shares $7.79 million -2.2%3.3%4.5 $1.72 4/15/20224,630,000 shares $8.84 million -0.4%3.4%4.9 $1.91 3/31/20224,650,000 shares $9.58 million -10.2%3.4%4.8 $2.06 3/15/20225,180,000 shares $8.96 million -3.2%3.8%5.1 $1.73 2/28/20225,350,000 shares $13.91 million -2.4%3.9%5.4 $2.60 2/15/20225,480,000 shares $17.37 million +3.0%4.0%7.1 $3.17 1/31/20225,320,000 shares $15.53 million +4.1%3.9%6 $2.92 1/15/20225,110,000 shares $16.86 million +5.6%3.7%5.9 $3.30 12/31/20214,840,000 shares $18.15 million +29.4%3.5%5.8 $3.75 12/15/20213,740,000 shares $13.76 million +10.7%2.7%4.4 $3.68 11/30/20213,380,000 shares $14.03 million +8.3%2.5%3 $4.15 11/15/20213,120,000 shares $13.57 million +5.8%2.3%1.6 $4.35 10/29/20212,950,000 shares $14.96 million -3.9%2.2%1.5 $5.07 10/15/20213,070,000 shares $16.36 million -8.4%2.2%1.6 $5.33 9/30/20213,350,000 shares $17.32 million -44.9%2.4%1.8 $5.17 9/15/20216,080,000 shares $32.83 million +47.9%4.4%3.3 $5.40 8/31/20214,110,000 shares $21.25 million +41.2%3.0%2.5 $5.17 8/13/20212,910,000 shares $11.61 million +8.2%2.1%4 $3.99 7/30/20212,690,000 shares $9.60 million -5.6%2.0%3.3 $3.57 7/15/20212,850,000 shares $10.66 million -5.0%2.1%3.3 $3.74 6/30/20213,000,000 shares $12.78 million -21.7%2.2%3.5 $4.26 6/15/20213,830,000 shares $15.86 million -2.5%2.8%4.2 $4.14 5/28/20213,930,000 shares $19.77 million -1.8%2.9%4.7 $5.03 5/14/20214,000,000 shares $18.24 million -0.7%N/A4.8 $4.56 4/30/20214,030,000 shares $23.29 million +5.0%N/A4.6 $5.78Is this Elon’s true agenda? (Ad)All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors have all turned to my business partner and I for our thoughts on the market. And with every investor in America wondering what Elon is going to do now that he's in Washington, this is what we tell themClick here for my report 4/15/20213,840,000 shares $19.35 million +27.2%N/A4.4 $5.04 3/31/20213,020,000 shares $15.25 million +64.1%N/A3.1 $5.05 3/15/20211,840,000 shares $10.08 million -0.5%N/A1.5 $5.48 2/26/20211,850,000 shares $10.99 million +22.5%N/A1.3 $5.94 2/12/20211,510,000 shares $10.01 million +4.9%N/A1 $6.63 1/29/20211,440,000 shares $7.89 million +8.3%N/A0.9 $5.48 1/15/20211,330,000 shares $8.11 million -64.1%N/A0.8 $6.10 12/31/20203,700,000 shares $20.02 million +31.2%N/A2 $5.41 12/15/20202,820,000 shares $11.56 million No ChangeN/A1.7 $4.10 11/30/20202,820,000 shares $13.85 million -5.1%N/A2.1 $4.91 11/15/20202,970,000 shares $14.82 million -35.0%N/A2.5 $4.99 10/30/20204,570,000 shares $20.70 million -29.0%N/A4.1 $4.53 10/15/20206,440,000 shares $51.20 million +21.1%N/A7 $7.95 9/30/20205,320,000 shares $42.45 million +8.6%N/A7.5 $7.98 9/15/20204,900,000 shares $49.39 million +50.8%N/A6.3 $10.08 8/31/20203,250,000 shares $28.28 million -18.8%N/A4.1 $8.70 8/14/20204,000,000 shares $32.04 million +2.8%N/A1.3 $8.01 7/31/20203,890,000 shares $36.37 million +3.5%N/A1.2 $9.35 7/15/20203,760,000 shares $31.96 million +1.1%N/A1.2 $8.50 6/30/20203,720,000 shares $34.56 million -5.6%N/A1.2 $9.29 6/15/20203,940,000 shares $41.09 million +605.1%N/A1.3 $10.43 5/29/2020558,800 shares $6.19 million +39.4%N/A0.2 $11.07 5/15/2020401,000 shares $1.74 million -45.2%N/A0.7 $4.35 4/30/2020731,400 shares $2.46 million -10.0%N/A1.6 $3.36 4/15/2020812,400 shares $2.68 million +14.7%0.9%1.6 $3.30 3/31/2020708,600 shares $2.44 million +70.5%0.8%0.4 $3.45 3/13/2020415,600 shares $1.25 million -11.4%0.5%1.1 $3.01 2/28/2020468,800 shares $1.32 million -28.2%0.5%0.2 $2.81 2/14/2020653,000 shares $2.00 million +11.8%0.7%0.3 $3.06 ADAP Short Interest - Frequently Asked Questions What is Adaptimmune Therapeutics' current short interest? Short interest is the volume of Adaptimmune Therapeutics shares that have been sold short but have not yet been closed out or covered. As of January 15th, investors have sold 5,760,000 shares of ADAP short. Learn More on Adaptimmune Therapeutics' current short interest. What is a good short interest ratio for Adaptimmune Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ADAP shares currently have a short interest ratio of 3.0. Learn More on Adaptimmune Therapeutics's short interest ratio. Is Adaptimmune Therapeutics' short interest increasing or decreasing? Adaptimmune Therapeutics saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 5,760,000 shares, an increase of 4.7% from the previous total of 5,500,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Adaptimmune Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Adaptimmune Therapeutics: Humacyte, Inc. (24.56%), Stoke Therapeutics, Inc. (16.52%), Erasca, Inc. (20.28%), AnaptysBio, Inc. (25.47%), Xeris Biopharma Holdings, Inc. (6.95%), Mind Medicine (MindMed) Inc. (38.30%), Akebia Therapeutics, Inc. (8.25%), Mineralys Therapeutics, Inc. (7.93%), Entrada Therapeutics, Inc. (8.59%), Cartesian Therapeutics, Inc. (23.26%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($4.18 billion), Charter Communications, Inc. ($3.91 billion), Reddit, Inc. ($3.16 billion), The Kroger Co. ($2.75 billion), International Paper ($2.57 billion), Cencora, Inc. ($2.06 billion), SoFi Technologies, Inc. ($2.06 billion), Rivian Automotive, Inc. ($2.00 billion), Live Nation Entertainment, Inc. ($1.63 billion), and Hims & Hers Health, Inc. ($1.57 billion). View all of the most shorted stocks. What does it mean to sell short Adaptimmune Therapeutics stock? Short selling ADAP is an investing strategy that aims to generate trading profit from Adaptimmune Therapeutics as its price is falling. ADAP shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Adaptimmune Therapeutics? A short squeeze for Adaptimmune Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ADAP, which in turn drives the price of the stock up even further. How often is Adaptimmune Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ADAP, twice per month. The most recent reporting period available is January, 15 2025. More Short Interest Resources from MarketBeat Related Companies HUMA Short Interest Data STOK Short Interest Data ERAS Short Interest Data ANAB Short Interest Data XERS Short Interest Data MNMD Short Interest Data AKBA Short Interest Data MLYS Short Interest Data TRDA Short Interest Data RNAC Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ADAP) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
